Go Deep
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,629 | 5.2 | 2.44 | 0.01 | 391.41 |
| Oct 2026 | 21,532 | 5.3 | 2.48 | 0.01 | 397.83 |
| Oct 2026 | 21,411 | 5.3 | 2.54 | 0.01 | 407.38 |
| Oct 2026 | 21,496 | 5.3 | 2.50 | 0.01 | 399.70 |
| Oct 2026 | 21,484 | 5.4 | 2.51 | 0.01 | 401.07 |
| Oct 2026 | 21,362 | 5.5 | 2.56 | 0.01 | 410.55 |
| Oct 2026 | 21,544 | 5.3 | 2.48 | 0.01 | 395.35 |
| Oct 2026 | 21,508 | 5.3 | 2.49 | 0.01 | 397.39 |
Arbutus Biopharma Corporation Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,014,000.0 | 179,126,000.0 | 1,051,000.0 | 529,000.0 |
| Net Profit | -5,143,000.0 | 169,695,000.0 | -3,756,000.0 | -7,742,000.0 |
| EPS | -0.0 | 0.9 | — | -0.0 |
Arbutus Biopharma Corporation Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 14,083,000.0 | 6,171,000.0 | 18,141,000.0 | 39,019,000.0 | — |
| Net Profit | -33,501,000.0 | -69,920,000.0 | -72,849,000.0 | -69,456,000.0 | — |
| EPS | -0.2 | -0.4 | -0.4 | -0.5 | — |
Arbutus Biopharma Corporation Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 94,618,000.0 | 131,707,000.0 | 144,401,000.0 | 195,419,000.0 | — |
| Total Liabilities | 18,042,000.0 | 34,341,000.0 | 38,383,000.0 | 58,567,000.0 | — |
| Total Equity | 76,576,000.0 | 97,366,000.0 | 106,018,000.0 | 136,852,000.0 | — |
Owes vs Owns
Arbutus Biopharma Corporation owed $0.06 for every $1 it owned in Jun 2026, down from $0.30 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.06× | 0.19× | 0.26× | 0.27× | 0.30× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Arbutus Biopharma Corporation Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 96.7%Receivables 1.5%Other assets 1.8%
How it's funded — Dec 2025
Short-term debt 0.6%Payables 1.2%Other liabilities 17.0%Shareholders' equity 80.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 91.5 | 122.6 | 126.0 | 146.9 |
| Receivables | 1.4 | 2.4 | 1.8 | 1.4 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 4.4 | 6.1 | 6.8 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 6.3 | 37.4 |
| Other assets | 1.7 | 2.3 | 4.2 | 3.0 |
| Liabilities & equity | ||||
| Short-term debt | 0.5 | 0.5 | 0.4 | 0.4 |
| Long-term debt | 0.2 | 0.8 | 1.3 | 1.8 |
| Payables | 1.2 | 2.3 | 3.2 | 3.5 |
| Other liabilities | 16.1 | 30.7 | 33.4 | 52.9 |
| Shareholders' equity | 76.6 | 97.4 | 106.0 | 136.9 |
| Net tangible assets | 76.6 | 97.4 | 106.0 | 136.9 |
Arbutus Biopharma Corporation Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -39,637,000.0 | -64,850,000.0 | -85,936,000.0 | -35,356,000.0 | — |
| Investing Activities | 15,580,000.0 | 22,948,000.0 | 50,773,000.0 | -74,942,000.0 | — |
| Financing Activities | 5,721,000.0 | 51,996,000.0 | 30,647,000.0 | 31,814,000.0 | — |